52 results on '"Gunn, Roger"'
Search Results
2. Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge
3. Application of Aligned-UMAP to longitudinal biomedical studies
4. Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
5. Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region
6. Imaging in Central Nervous System Drug Discovery
7. Non linear mixed effects analysis in PET PK-receptor occupancy studies
8. Mathematical modelling of [11C]-(+)-PHNO human competition studies
9. A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies
10. Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo
11. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET
12. Statistical estimation with Kronecker products in positron emission tomography
13. A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [ 123i]CNS 1261
14. Kinetic modelling of [ 123I]CNS 1261—a potential SPET tracer for the NMDA receptor
15. PET measurement of the influence of corticosteroids on serotonin-1A receptor number
16. β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro: Implications for Antidepressant Therapy
17. Drug action at the 5-HT 1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [ carbonyl- 11C]WAY-100635
18. Quantitative analysis of [ carbonyl- 11C]WAY-100635 PET studies
19. TAUIQ: A QUANTITATIVE ALGORITHM TO INCREASE THE POWER OF TAU PET IMAGING IN CLINICAL TRIALS
20. TAUIQ - A QUANTITATIVE ALGORITHM TO INCREASE THE POWER OF TAU PET IMAGING IN CLINICAL TRIALS
21. RELATIONSHIP BETWEEN ASTROCYTE ACTIVATION USING [11C]BU99008 PET, GLUCOSE METABOLISM AND AMYLOID IN ALZHEIMER’S DISEASE: A DEMENTIA PLATFORM UK EXPERIMENTAL MEDICINE STUDY
22. EVALUATION OF NOVEL ASTROCYTE MARKER [11C]BU99008 PET IN ALZHEIMER’S DISEASE: A DEMENTIA PLATFORM U.K. EXPERIMENTAL MEDICINE STUDY
23. CALCULATION OF AβL WITH THE IQAβ ALGORITHM ENABLES AUTOMATIC AND REPRODUCIBLE CLASSIFICATION OF [18F]-FLORBETAPIR SCANS
24. BASELINE CHARACTERISTICS FOR PATIENTS WITH MILD ALZHEIMER’S DISEASE ENROLLED IN THE PHASE IIA TRIAL OF ACTIVE IMMUNOTHERAPEUTIC VACCINE UB-311
25. AMYLOID LOAD: A NOVEL BIOMARKER WITH INCREASED SENSITIVITY FOR β-AMYLOID
26. PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY
27. PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY
28. Evaluation of the in vivo ED50 for the PET Radioligand, [11C]GSK-215083, in Papio anubis
29. Within-subject comparison of the sensitivity of [11C]-(+)-PHNO and [11C]raclopride to amphetamine induced changes in endogenous dopamine in healthy human volunteers
30. PET imaging of dopamine D3 receptors in humans with [11C]-(+)-PHNO: dissection of PHNO signal using two highly selective D3 antagonists
31. PBR28, PBR06 and PBR111 bind two distinct TSPO sites in human brain tissue
32. A combined diffusion tensor imaging (DTI) and [11C]-(+)-PHNO positron emission tomography (PET) study to quantify dopamine D3/D2 receptors in pallidum
33. Awake nonhuman primate brain PET imaging without head restraint
34. Pharmacokinetic characterization of compounds with increased target residence times using PET
35. Comparison of nonlinear mixed effects and conventional least squares analyses of PET PK-receptor occupancy studies
36. Graphical analysis of occupancy studies for radioligands with irreversible kinetics
37. PET measurement of nicotine evoked dopamine release
38. Effect of cellular compartments on the binding of [3H](+)PhNO to the porcine D2/D3-DAR
39. A pseudo-reference region method applied to measurement of GlyT1 occupancy in human brain using [11C]GSK931145 and PET
40. Uptake and regional distribution of [11C]rofecoxib in human brain
41. PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRB06, and [F-18]PBR111 in nonhuman primate
42. Predicting the in vivo performance of TSPO PET radioligands using a biomathematical modelling approach
43. In vivo binding of antipsychotics to D3 and D2 receptors: A PET study in baboons with [11C]-(+)-PHNO
44. Differentiation of the Mu-opioid ligand GSK1521498 from naltrexone using [11C]carfentanil PET and fMRI
45. Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, Mild Cognitive Impairment and healthy controls
46. Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, mild cognitive impairment, and healthy controls
47. P1-265: Voxel-based analysis of C11 Pittsburgh compound B for diagnosing Alzheimer's disease
48. P1-237: PET amyloid imaging with Pittsburgh compound B in Alzheimer's disease, mild cognitive impairment, and healthy controls
49. A database of [11C]WAY-100635 binding in healthy volunteers: relationship to demographic, physiological and personality variables
50. Characterisation of the Appearance of Radioactive Metabolites in Monkey and Human Plasma from the 5-HT 1A Receptor Radioligand, [ carbonyl- 11C]WAY-100635—Explanation of High Signal Contrast in PET and an Aid to Biomathematical Modelling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.